Chugai Pharmaceutical Co., Ltd. (TYO:4519)

Market Cap	10.03T
Revenue (ttm)	1.20T
Net Income (ttm)	395.44B
Shares Out	1.65B
EPS (ttm)	240.29
PE Ratio	25.35
Forward PE	22.36
Dividend	100.00 (1.64%)
Ex-Dividend Date	Dec 29, 2025

Volume	8,274,100
Average Volume	2,993,730
Open	6,100.00
Previous Close	6,092.00
Day's Range	6,089.00 - 6,210.00
52-Week Range	5,823.00 - 8,655.00
Beta	0.69
RSI	25.17
Earnings Date	Jul 24, 2025

About The Aaron's Company

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 5,026
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4519

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.

Financial numbers in CAD